Tempest Therapeutics, Inc. Profile Avatar - Palmy Investing

Tempest Therapeutics, Inc.

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is cu…

Biotechnology
US, South San Francisco [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of TPST's Analysis
CIK: 1544227 CUSIP: 87978U108 ISIN: US87978U1088 LEI: - UEI: -
Secondary Listings
TPST has no secondary listings inside our databases.